Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Boosting anti-PD-1 PD-L1 therapy by targeting YTHDF1
Advanced Tech.
5 min read
Boosting anti-PD-1 PD-L1 therapy by targeting YTHDF1
20 July 2023
YTH domain-containing family protein 1 (YTHDF1) is a translation-promoting m6A reader that targets mRNAs in the cytoplasm and contributes to tumor progression by regulating cell proliferation, DNA damage, and immunity.
Read →
Top 50 Pharmaceutical Companies R&D Progress: An Overview of STADA Arzneimittel's 19 Drug Pipelines
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of STADA Arzneimittel's 19 Drug Pipelines
20 July 2023
STADA Arzneimittel AG is a pharmaceutical organization that was founded in 1895 and is based in Hessen, Germany.
Read →
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Jazz's 61 Drug Pipelines
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Jazz's 61 Drug Pipelines
20 July 2023
Jazz Pharmaceuticals Plc is a pharmaceutical company that was founded in 2003 and is headquartered in Dublin, Ireland.
Read →
Breaking Through the Blood-Brain Barrier: P-Selectin-Targeted Nanocarriers Promote Active Crossing
Advanced Tech.
5 min read
Breaking Through the Blood-Brain Barrier: P-Selectin-Targeted Nanocarriers Promote Active Crossing
20 July 2023
Fucoidan-based nanocarriers can actively transport therapeutic cargo across tumor endothelium, allowing for targeted delivery to the tumor microenvironment. This approach holds immense potential to revolutionize therapeutic outcomes for diseases with an intact BBB, such as SHH-MB, and could usher in a new era of improved therapies for a multitude of brain diseases.
Read →
The Dual Boom of Bispecific Antibodies: Market and Drug Discovery Pipeline
Advanced Tech.
6 min read
The Dual Boom of Bispecific Antibodies: Market and Drug Discovery Pipeline
18 July 2023
They have gained broad potential in preclinical and clinical investigations in a variety of tumor types following regulatory approval of newly developed technologies involving bispecific and multispecific antibodies.
Read →
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
Valuable Targets
10 min read
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
17 July 2023
the discovery and development of USP1 inhibitors certainly open up new frontiers for the treatment of a variety of diseases, including cancer, diabetes, and potentially even more.
Read →
No sequence will be left unexplored with Patsnap Bio!
Bio Sequence
4 min read
No sequence will be left unexplored with Patsnap Bio!
17 July 2023
In order to address the risk of missed detection brought by degenerate sequences, the Patsnap Engineering team utilizes its self-developed NLP, CV, entity recognition, anaphora resolution and other technologies to construct a deep learning model.
Read →
The GLP-1R plus strategy for curbing the obesity epidemic
Hot Spotlight
5 min read
The GLP-1R plus strategy for curbing the obesity epidemic
14 July 2023
this approach brings new hope that we can finally address the growing concern of obesity worldwide.
Read →
Cdc42 provides a new target for treating Alzheimer’s Disease
Cdc42 provides a new target for treating Alzheimer’s Disease
13 July 2023
the small G protein family member, Cdc42, plays an important role in the progression of Alzheimer's disease.
Read →
Discovery of a New Drug for Inflammatory and Autoimmune Diseases: TAK-279
Drug Insights
4 min read
Discovery of a New Drug for Inflammatory and Autoimmune Diseases: TAK-279
12 July 2023
TAK-279, which is a highly selective inhibitor of TYK2 enzymatic activity.
Read →
Organoid-On-Chips: A Potential Game Changer for Clinical Studies
Advanced Tech.
5 min read
Organoid-On-Chips: A Potential Game Changer for Clinical Studies
12 July 2023
HRS-1893 works through a special mechanism that inhibits myocardial excessive contraction and is intended for the treatment of hypertrophic cardiomyopathy and heart failure caused by myocardial hypertrophy.
Read →
Behind the Approval of Lecanemab: A Decade of Hardship Cannot Dampen Passion
Drug Insights
6 min read
Behind the Approval of Lecanemab: A Decade of Hardship Cannot Dampen Passion
11 July 2023
As the only Alzheimer's drug fully approved by the FDA in the last 20 years, it may genuinely bring a ray of hope to patients plagued by the disease worldwide.
Read →